Hormonal Acne in Special Populations: What It Looks Like and How Treatment Changes Across Your Life

Why "Special Populations" Matters for Hormonal Acne

Hormonal acne is not a single, static condition. It changes shape depending on your hormonal environment, and that environment shifts dramatically across a woman's life. A 17-year-old with irregular cycles, a 28-year-old trying to conceive, a 35-year-old postpartum and breastfeeding, and a 49-year-old in perimenopause may all present with deep, painful, cyclical jawline breakouts, but the underlying hormonal drivers and the treatments that are safe differ sharply between them.

Androgens, primarily testosterone and its more potent derivative dihydrotestosterone (DHT), bind to receptors in the sebaceous gland and directly increase sebum production. Women have far lower absolute androgen levels than men, yet their sebaceous glands express the same androgen receptors, which explains why even modest androgen fluctuations across the menstrual cycle cause clinically significant breakouts in susceptible women.

The sections below address each major population in turn, covering diagnosis, sex-specific physiology, and the treatments that are appropriate or off-limits at each stage.

Reproductive-Age Women: The Baseline Picture

Androgen-driven acne in reproductive-age women typically follows a predictable monthly pattern. Breakouts cluster in the week before menstruation, when estrogen falls and progesterone (which can convert peripherally to androgens) peaks. A 2001 survey of 400 women found that 44% reported premenstrual acne flares, with breakouts concentrated on the chin and jaw.

How to Recognize Hormonal Pattern

• Deep, tender nodules or cysts rather than surface comedones
• Predominantly lower-face distribution: jawline, chin, angle of the jaw
• Timing linked to the luteal phase (days 21 through 28 of a 28-day cycle)
• Resistance to standard over-the-counter benzoyl peroxide or salicylic acid alone

First-Line Treatment Options

Combined oral contraceptives (COCs) containing estrogen and an anti-androgenic progestin are the most studied hormonal approach. The FDA has approved three COCs specifically for acne: norgestimate/ethinyl estradiol (Ortho Tri-Cyclen), norethindrone acetate/ethinyl estradiol (Estrostep Fe), and drospirenone/ethinyl estradiol (Yaz). Drospirenone carries mild aldosterone-blocking activity, which may also reduce premenstrual bloating that often co-occurs with acne flares.

Spironolactone 50 to 100 mg daily is a widely used off-label option for women who cannot or prefer not to use COCs. It blocks the androgen receptor directly. A 2017 retrospective cohort of 110 women showed that 66% achieved a "clear" or "almost clear" rating on the Investigator's Global Assessment after six months at doses of 100 mg daily.

Women with PCOS: The Most Undertreated Group

Women with polycystic ovary syndrome represent the population where hormonal acne is most severe, most persistent, and most often undertreated because clinicians focus on metabolic and fertility concerns and defer acne management. PCOS affects 8 to 13% of reproductive-age women worldwide and acne is present in approximately 70% of affected women, making it one of the most clinically significant dermatologic manifestations of the syndrome.

Why PCOS Acne Behaves Differently

In PCOS, elevated LH signaling drives excess ovarian androgen production, and insulin resistance compounds this by reducing sex hormone-binding globulin (SHBG), which frees more testosterone to reach the sebaceous gland. The result is acne that is often more inflammatory, more likely to scar, and more resistant to topical therapies compared with acne in women without PCOS.

The Endocrine Society's 2023 PCOS clinical practice guideline recommends COCs as first-line pharmacologic therapy for hyperandrogenism manifestations including acne, with spironolactone as an appropriate add-on or alternative.

Insulin-Sensitizing Agents and Acne

Metformin reduces insulin-driven androgen production. Its effect on acne is more modest than on metabolic parameters. A meta-analysis in Fertility and Sterility found that metformin reduced free androgen index in women with PCOS but produced less direct improvement in acne scores compared with COCs. Metformin may be appropriate when the woman is also trying to conceive or when COCs are contraindicated.

Screening Reminder

Any woman with severe or sudden-onset acne alongside irregular periods, hirsutism, or scalp hair thinning should have a basic PCOS workup: total and free testosterone, DHEA-S, LH/FSH ratio, and fasting glucose or HOMA-IR. Do not treat the acne in isolation.

Pregnancy: What Is Safe and What Is Absolutely Off-Limits

Pregnancy changes acne in unpredictable ways. The first trimester frequently worsens breakouts as progesterone surges; some women improve by the second trimester as the placenta takes over progesterone production and sebum output stabilizes. Approximately 42% of women experience worsening acne during pregnancy, particularly during the first trimester.

Contraindicated treatments in pregnancy:

Isotretinoin (Accutane) is absolutely contraindicated in pregnancy. It is one of the most potent human teratogens known. The iPLEDGE REMS program mandates monthly pregnancy testing and two forms of contraception for all patients of childbearing potential. Isotretinoin causes craniofacial, cardiac, and central nervous system malformations; the risk is present at any dose across the first trimester. If you are trying to conceive, stop isotretinoin at least one month before attempting pregnancy, per FDA labeling.

Oral tetracyclines (doxycycline, minocycline) are contraindicated from the second trimester onward because they deposit in fetal bone and developing teeth, causing permanent discoloration. They should be stopped as soon as pregnancy is confirmed if use extended past the first trimester.

Spironolactone is contraindicated in pregnancy due to theoretical risk of feminization of a male fetus from androgen receptor blockade. Women taking spironolactone for acne must use reliable contraception, and the drug should be stopped immediately upon a positive pregnancy test.

Options that may be used with caution in pregnancy:

Topical azelaic acid (15 to 20%) is FDA pregnancy category B and is considered the safest prescription topical for acne in pregnancy. Topical clindamycin is also generally considered low-risk, with minimal systemic absorption. Topical benzoyl peroxide has a long safety record and is widely used.

Topical tretinoin (retinoid) carries theoretical teratogenicity concern based on oral retinoid data, though systemic absorption is very low. ACOG advises that topical retinoids should generally be avoided in pregnancy, particularly the first trimester, because data are insufficient to confirm safety. Shared decision-making applies.

Postpartum and Lactation: A Window Often Ignored

The postpartum period produces a specific hormonal shift: estrogen and progesterone crash after delivery, and prolactin rises to support lactation. As the cycle returns, sometimes erratically, androgen levels fluctuate before ovarian function fully normalizes. Many women experience their worst-ever acne flare in the three to six months postpartum, exactly when they are most sleep-deprived and least likely to have a dermatology appointment.

What Is Safe While Breastfeeding

Topical azelaic acid, benzoyl peroxide, and topical clindamycin are considered compatible with breastfeeding because systemic absorption is negligible. Apply topicals away from the chest if nursing.

Oral antibiotics require more care. Erythromycin is the preferred oral antibiotic during lactation. Doxycycline transfers into breast milk and is generally avoided for extended courses, though short courses (<3 weeks) are sometimes used when benefit is judged to outweigh risk.

Spironolactone does transfer into breast milk. The LactMed database classifies spironolactone as probably compatible with breastfeeding at low doses, but notes the data are limited. Most clinicians defer spironolactone until the woman has finished breastfeeding.

COCs containing estrogen may reduce milk supply in early lactation; progestin-only pills (the "mini-pill") are preferred if hormonal contraception is started before six weeks postpartum.

Isotretinoin is contraindicated during breastfeeding. It should not be initiated until breastfeeding has fully stopped.

Perimenopause and Menopause: New Acne, Old Frustration

Acne in perimenopause and menopause is one of the least-discussed dermatologic consequences of the hormonal transition, yet it is a real and common complaint. As estrogen declines during perimenopause, the relative androgenic environment shifts. SHBG falls, freeing more testosterone. Sebaceous glands, no longer balanced by the anti-sebogenic effects of estrogen, respond with increased output. Many women in their late 40s and early 50s report acne they have never experienced before, or a return after decades of clear skin.

A Framework for Thinking About Perimenopausal Acne

Consider three distinct presentations:

1. Persistence from reproductive years: The woman who has had hormonal acne since her 20s and finds it worsening as cycles become irregular. Here, anti-androgen therapy (spironolactone) often continues to be effective and COCs remain an option for women without contraindications up to menopause if they are non-smokers under 50.

2. New onset in perimenopause: The woman with no prior acne history who develops deep jawline breakouts alongside hot flashes or cycle changes. A screen for late-onset hyperandrogenism or adrenal androgen excess is reasonable before attributing acne purely to perimenopause.

3. Post-menopausal acne: Acne after at least 12 months of amenorrhea is less common but occurs. Spironolactone remains useful. A small open-label study found spironolactone 100 mg effective in post-menopausal women with acne, with improvements noted at 12 weeks.

Does Menopausal Hormone Therapy (MHT) Help or Hurt?

The relationship between MHT and acne is nuanced. Estrogen-dominant MHT may modestly improve acne by raising SHBG and reducing free androgens. Progestins vary: androgenic progestins (norethindrone, levonorgestrel) may worsen acne, while anti-androgenic progestins (drospirenone, micronized progesterone) are less likely to. The Menopause Society's 2023 position statement notes that progestin type in MHT influences androgenic side effects, including acne and hirsutism. Women on MHT who develop new acne should have their progestin component reviewed.

Adolescent Girls: When Hormonal Acne First Appears

Adolescent acne deserves mention because the initial hormonal acne that appears with adrenarche (the rise of adrenal androgens at puberty) sets the pattern for adult disease. Girls with early adrenarche, higher BMI, or a family history of PCOS are at greater risk for persistent adult hormonal acne.

Treatment considerations differ here because:

• COCs are appropriate for adolescent girls (typically from age 15 onward when indicated for acne) and may provide cycle regulation alongside acne control
• Isotretinoin requires the same iPLEDGE enrollment for girls of childbearing potential, including monthly pregnancy tests, even if the patient reports no sexual activity
• ACOG supports prescribing COCs to adolescents for acne and other menstrual indications without requiring pelvic exam as a prerequisite for the prescription

Tetracyclines remain a standard adjunct for adolescent inflammatory acne but should be paused and reconsidered if the patient becomes pregnant.

Who This Is Right For, and Who Needs a Different Approach

Not every woman with acne has a hormonal driver. Red flags that suggest a non-hormonal or secondary cause include:

• Sudden severe onset, especially in a woman over 40 with no prior history
• Acne accompanied by significant virilization (voice deepening, clitoromegaly, rapid muscle gain)
• Androgen levels markedly above the upper limit of normal for women (total testosterone >150 ng/dL warrants evaluation for adrenal or ovarian tumor)

Women with the following profiles respond best to hormonal acne approaches:

| Profile | Preferred First-Line Option | |---|---| | Reproductive age, needs contraception | COC with anti-androgenic progestin | | Reproductive age, no contraception needed | Spironolactone 50 to 100 mg | | PCOS, not trying to conceive | COC plus spironolactone if needed | | PCOS, actively trying to conceive | Topical azelaic acid, avoid systemic anti-androgens | | Pregnant | Topical azelaic acid, topical clindamycin | | Breastfeeding | Topical azelaic acid, erythromycin oral if severe | | Perimenopausal | Spironolactone, review MHT progestin type | | Post-menopausal | Spironolactone 50 to 100 mg |

The Evidence Gap: What We Do Not Know About Women Specifically

Women have been underrepresented in acne trials as a distinct physiologic population, not merely as female participants in mixed-sex studies. Most large acne RCTs enroll women at a higher rate than men because adult hormonal acne skews female, but they rarely stratify results by menstrual cycle phase, hormonal contraceptive use, life stage, or PCOS status. This matters clinically.

For example, the SAPPHIRE trial of clascoterone cream (a topical androgen receptor antagonist approved by the FDA in 2020) enrolled both male and female participants but did not report subgroup analyses by menstrual cycle phase or hormonal contraceptive use. We do not know whether women on COCs derived the same benefit as those not using hormonal contraception, because that question was not asked.

A 2022 Cochrane review on interventions for acne concluded that the quality of evidence for most topical and systemic treatments is moderate to low, with few trials designed to assess hormonal variables in women. This is not a reason to avoid treatment. It is a reason to be specific about what the data actually show versus what is inferred from mixed populations.

Diagnosis: How Hormonal Acne Is Confirmed Clinically

No blood test diagnoses hormonal acne. The diagnosis is clinical, based on pattern, timing, and response history. Bloodwork becomes relevant when:

• Acne is severe and not responding to standard care
• There are signs of hyperandrogenism beyond acne (hirsutism score above 8 on the Ferriman-Gallwey scale, irregular cycles, scalp hair loss)
• A woman is being considered for spironolactone and her potassium status needs baseline assessment

Useful labs in that context: total testosterone, free testosterone (or SHBG to calculate it), DHEA-S, 17-hydroxyprogesterone (to rule out late-onset congenital adrenal hyperplasia), and basic metabolic panel if starting spironolactone. The Endocrine Society recommends measuring free or total testosterone to evaluate hyperandrogenism before diagnosing PCOS.

"Acne is often the most visible and distressing sign of androgen excess in women, yet it is also the one most likely to be handed off to dermatology without a hormonal workup," said Dr. Rachel Goldberg, MD, WomanRx Editorial Board Member and women's health specialist. "When a woman has cyclical jawline acne and irregular periods, that combination deserves an endocrine lens, not just a prescription for antibiotics."